Denis Gestin appointed as Chairman of Holistick Medical – first startup funded by Truffle Capital’s BioMedTech Crossover Fund
Paris, October 10, 2018
Truffle Capital, an independent venture capital firm focused on creating and financing start-ups with disruptive technologies in life sciences and information technology, today announces the appointment of Denis Gestin, 54, as Chairman of the Board of Directors of Holistick, the first startup company funded by Truffle Capital's new BioMedTech Crossover fund.
“We’re extremely pleased to welcome Denis Gestin as Chairman of the Board of Holistick. His extensive management experience and track record in successfully launching global medical technologies, including in cardiology, will go a long way for the development of the company and its future commercial success”, said Philippe Pouletty, MD, co-founder and CEO of Truffle Capital and his Truffle partners Antoine Pau, Alain Chevallier, and Vincent Gardès.
Denis Gestin, whose expertise in the field is recognized worldwide, has over 30 years of experience in the management and commercial development of medical technologies companies. Prior to joining Holistick’s Board of Directors, he had been serving as Senior Vice President of Global Commercial Integration at Abbott Laboratories, since January 2017. Beforehand, Mr. Gestin worked for more than 20 years at St. Jude Medical, where he held various executive positions in Europe, the Middle East, Africa, Canada and, more recently, as President of the International Division (OUS), up until 2017. Mr. Gestin began his career with Ela Medical Inc. (Livanova), where he worked in marketing and business development from 1988 to 1997. A graduate of EDC Paris Business School, Mr. Gestin is also a member of the Board of Directors of the Swedish company Acarix.
About Holistick Medical
Founded in 2017 by Truffle Capital, Holistick Medical is developing a minimally invasive medical device to close the patent foramen ovale, an abnormal communication between the right and left heart that can lead to serious strokes. Unlike currently available metallic devices, Holistick Medical offers a physiological and respectful approach to cardiac anatomy, based on an adhesive, flexible, lightactivated and biocompatible patch technology initially developed and patented jointly by Harvard, MIT, Boston Children's Hospital and Brigham and Women's Hospital.
Find out more: www.holistick-medical.com
About Truffle Capital
Founded in 2001, Truffle Capital is an independent European Venture Capital firm focused on radical innovations in Life Sciences (MedTech and BioTech) and breakthrough technologies in the IT sector (FinTech and InsurTech). Truffle Capital's mission is to support the founding and development of young innovative companies capable of becoming tomorrow’s leaders. Chaired by Patrick Kron and managed by Dr. Philippe Pouletty and Bernard-Louis Roques, Co-Founders and Chief Executive Officers, Truffle Capital has raised more than €1.1 billion since its creation and has supported several dozens of companies in the life sciences and digital technology sectors. In 2019, Truffle Capital announced the raising of nearly €400 million for its early-stage institutional funds, including €250 million dedicated to BioMedTech.
Find out more : www.truffle.com — Twitter : @trufflecapital